Litcius/Paper detail

Targeting SARS-CoV-2 non-structural protein 13 via helicase-inhibitor-repurposing and non-structural protein 16 through pharmacophore-based screening

Md. Nazmus Samdani, Niaz Morshed, Rumman Reza, Muhammad Asaduzzaman, Abul Bashar Mir Md. Khademul Islam

2022Molecular Diversity16 citationsDOIOpen Access PDF

Topics & Concepts

PharmacophoreRepurposingDrug repositioningSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)HelicaseVirologyVirtual screeningStructural proteinCoronavirus disease 2019 (COVID-19)Computational biologyDrug discoveryChemistryBiologyMedicineStereochemistryDrugPharmacologyBiochemistryVirusRNAInfectious disease (medical specialty)EcologyPathologyDiseaseGeneComputational Drug Discovery MethodsSARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches
Targeting SARS-CoV-2 non-structural protein 13 via helicase-inhibitor-repurposing and non-structural protein 16 through pharmacophore-based screening | Litcius